

## References

### I-9014

1. Zynteglo prescribing information. bluebird bio, Inc. August 2022.
2. Vichindky E, Levine L, et al. Standards of Care Guidelines for Thalassemia. 2012.
3. Thalassemia International Federation. 2021 Guidelines for the Management of Transfusion Dependent Thalassemia (TDT) 4th edition. Chapter 17. Pages 279-290.
4. Bluebird Bio. A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in  $\beta$ -Thalassemia Major Participants. ClinicalTrials.gov Identifier: NCT01745120.
5. Bluebird Bio. A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in  $\beta$ -Thalassemia Major (Also Referred to as Transfusion-dependent  $\beta$ -Thalassemia [TDT]) and Sickle Cell Disease. ClinicalTrials.gov Identifier: NCT02151526.
6. Bluebird Bio. A Study Evaluating the Safety and Efficacy of bb111 in Severe Sickle Cell Disease. ClinicalTrials.gov Identifier: NCT02140554.
7. Bluebird Bio. A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent  $\beta$ -Thalassemia, Who do Not Have a  $\beta^0/\beta^0$  Genotype. ClinicalTrials.gov Identifier: NCT02906202.
8. Bluebird Bio. A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent  $\beta$ -Thalassemia. ClinicalTrials.gov Identifier: NCT03207009.